Carmell
CTCX
Market cap $4.85M

0.2320 USD

-0.0500

17.73%

At close Nov 15, 4:00 PM EST

Pre-market

0.2200

-0.0120

5.17%

1 day

-17.73%

5 days

-20.30%

1 month

-32.89%

3 months

-76.08%

6 months

-90.04%

Year to date

-93.93%

1 year

-89.91%

5 years

-97.62%

10 years

-97.62%

About: Carmell Corp is a bio-aesthetics company that utilizes the Carmell Secretome to support skin and hair health. Its cosmetic skincare product portfolio includes Carmell G.L.E.E and various others in pipeline such as Youth restoring formula, Ultra-brightening formula, Ultra-hydrating formula, and Rapid Recovery formula among others. The company has one operating segment, principally the business of developing and commercializing bio-aesthetics and its bone and tissue healing products.

Employees: 10

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

54% more funds holding

Funds holding: 13 [Q2] → 20 (+7) [Q3]

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

1.72% more ownership

Funds ownership: 11.3% [Q2] → 13.02% (+1.72%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

65% less capital invested

Capital invested by funds: $3.08M [Q2] → $1.09M (-$1.99M) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CTCX.

See Analyst Rankings

Financial journalist opinion

Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index

Carmell Corp (Nasdaq: CTCX) announced the appointment of Kendra Bracken-Ferguson as CEO effective July 30, 2024 with Rajiv Shukla continuing as Chairman.

Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index

Carmell Announces Successful Closing of $3.0 Million Private Placement

PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of its previously announced private placement with new and existing investors (the “Private Placement”). The Company received gross proceeds from the Private Placement of $3 million, excluding offering expenses.

Carmell Announces Successful Closing of $3.0 Million Private Placement

Carmell Announces $3.0 Million Private Placement

PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expenses (the “Private Placement”).

Carmell Announces $3.0 Million Private Placement

Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction

PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the successful closing of the previously announced sale of its wholly owned subsidiary, Axolotl Biologix (“AxoBio”) to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and cancellation of $8 million in notes payable.

Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction

Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the execution of a definitive agreement to sell its wholly owned subsidiary, Axolotl Biologix (“AxoBio”) to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million. “The sale of AxoBio enables our exit from the tissue graft space thereby facilitating a sharper organizational focus on the launch of our skincare products beginning in March 2024 and continuing over Summer 2024,” said Rajiv Shukla, Chief Executive Officer of Carmell.

Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field

PITTSBURGH, March 18, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced it will host an Investor Webinar titled “Unveiling the Secretome: On the Eve of Product Launch” on March 20, 2024 at 3:00 PM ET to discuss Carmell Secretome™, the biggest technological revolution in regenerative skin and haircare to the fast-growing ~$500 billion aesthetics industry. To register, click here.

Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field

Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024

PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced that they have completed product development of their Gold Limited Edition Exclusive (G.L.E.E.) product for commercial launch in March 2024.

Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024

Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors

PITTSBURGH, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a human biomaterials company (“Carmell”), today announced the addition of two independent directors to their Board.

Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors

See News Rankings

Charts implemented using Lightweight Charts™